(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.74%.
Imunon's earnings in 2026 is -$14,733,162.On average, 7 Wall Street analysts forecast IMNN's earnings for 2026 to be -$13,307,442, with the lowest IMNN earnings forecast at -$15,892,616, and the highest IMNN earnings forecast at -$10,252,033. On average, 7 Wall Street analysts forecast IMNN's earnings for 2027 to be -$10,660,543, with the lowest IMNN earnings forecast at -$16,662,500, and the highest IMNN earnings forecast at -$6,245,492.
In 2028, IMNN is forecast to generate -$7,812,756 in earnings, with the lowest earnings forecast at -$10,173,474 and the highest earnings forecast at -$6,186,572.